期刊
CURRENT RHEUMATOLOGY REVIEWS
卷 6, 期 2, 页码 138-144出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157339710791330768
关键词
Systemic sclerosis; lung; outcome measures
类别
资金
- National Institutes of Health [NIAMS K23 AR053858-03]
- Scleroderma Foundation
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR053858] Funding Source: NIH RePORTER
Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the current evidence based medicine regarding available therapies for SSc-ILD; discusses the lessons learned from recent SSc-ILD randomized controlled trials (RCTs); and proposes outcome measures and recommendations for design of future RCTs for SSc-ILD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据